

New study highlights the clinical value of UBC® Rapid in detecting invasive bladder cancer

A recently published scientific study has provided further evidence to support the use of UBC® Rapid as a diagnostic and monitoring tool for bladder cancer.

This multicenter study, conducted by Ecke et al. in Germany and published in the Official Journal of the Society of Urologic Oncology, analyzed 732 urine samples. The aim was to compare the diagnostic accuracy of urinary cytology with other urine-based point-of-care tests that are commercially available. This study stands out as the first to compare all available rapid tests on a large group of bladder cancer patients and healthy controls in a single setting.

The results of the study indicated that the UBC® Rapid test effectively differentiated between patients with bladder cancer and healthy controls, based on cytokeratin concentrations. These findings further support previous research and demonstrate the high detection rates of bladder cancer cases, particularly for high-grade bladder cancer patients, using the UBC Rapid test.

In addition to its diagnostic capabilities, the study highlighted the potential clinical value of the UBC® Rapid test as a urinary biomarker for detecting high-grade non-muscle invasive bladder cancer patients. This discovery could greatly aid in the management of these particular tumors.

The link for the article is:

<https://www.sciencedirect.com/science/article/abs/pii/S1078143923002259>

About UBC®

UBC® is a quantitative in vitro diagnostic test for the prognosis and monitoring of patients with bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. Elevated amounts of cytokeratin fragments are found in the urine of many individuals with bladder cancer, even in the early stages of the disease. UBC® is also available as a quantitative POC test.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[New study highlights the clinical value of UBC® Rapid in detecting invasive bladder cancer](#)